Slide background

Serum Institute Of India


Serum Institute of India

Serum Institute of India Pvt. Ltd. ( is the world’s largest vaccine manufacturer by number of doses produced and sold globally (over 1.3 billion doses).  This also makes Serum Institute the largest global manufacturer of complex biologicals (including proteins, monoclonal antibodies and vaccines).  Approximately two of every three children immunized globally are vaccinated with one of Serum Institute’s over 50 products. Since its founding in 1966 by Dr. C.S. Poonawalla, Serum Institute products have been used over many decades in approximately 170 countries.

Through Serum Institute, India was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by the DTP group of vaccines and later, for the MMR group of vaccines. The Philanthropic philosophy of Serum Institute was then expanded to reduce the prices of newer vaccines such as Hepatitis-B vaccine, Rabies vaccine and Combination vaccine. Today, Serum Institute has the strategic and commercial vision to replicate their success in vaccines with biosimilars, making them available at sufficient volume, quality and price to deliver these valuable medicines to patients globally.

The recent introduction of biosimilar erythropoietin (EPO) from Serum Institute into the Indian market is informative on the power of quality, capacity and corporate branding for trusted products.  Outside their historical business dedicated to vaccines, Serum Institute developed a biosimilar of EPO. Serum Institute’s biosimilar EPO was the 11th alternative to the originator EPO sold by Amgen (Epogen) or Johnson & Johnson (Eprex outside the USA) or the other EPO products classified in India as ‘similar biologics’. Despite entering the Indian market for EPO late, Serum Institute became the largest provider of EPO in India after only 18 months.

Serum Institute’s fully human IgG1 monoclonal antibody, Rabishield®, is another demonstration of their ability to develop, manufacture and commercialise high quality and affordable complex biologics. In 2017, Rabishield® was launched by Serum Institute following collaboration with the University of Massachusetts Medical School. The product provided a first of its kind treatment in a form that is more potent, easier to manufacturer and at a significant price discount to existing treatments. Rabishield® fulfilled unmet patient demand in countries where existing standards of care were financially out of reach and where rabies was continuing to cause significant loss of life.

Contact Us

Not readable? Change text. captcha txt